Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - bcg strain - powder for solution for instillation - bcg strain 200 - 800 miu - bcg vaccine - bcg vaccine - oncotice is used as a treatment of flat urothelial cell carcinoma in situ (cis) of the bladder and as an adjuvant therapy after transurethral resection (tur) of a primary or relapsing superficial papillary urothelial cell carcinoma of the bladder stage ta (grade 2 or 3) or t1 (grade 1 2 or 3). oncotice is only recommended for stage ta grade 1 papillary tumors when there is judged to be a high risk of tumor recurrence.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

qpharma pty ltd - tetracycline hydrochloride - oral solution/suspension - tetracycline hydrochloride antibiotic active 200.0 g/kg - antibiotic & related - birds - ornamental | domestic birds | amazon parrot | aviary bird | budgerigar | cage birds | caged bird | canary | cockatiel | - bacterial enteritis | tetracycline sensitive bacteria | post-weaning bacterial enterit

European Union - English - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - ziconotide - injections, spinal; pain - analgesics - ziconotide is indicated for the treatment of severe, chronic pain in patients who require intrathecal (it) analgesia.

European Union - English - EMA (European Medicines Agency)

recordati netherlands b.v. - tivozanib - carcinoma, renal cell - antineoplastic agents - fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (rcc) and for adult patients who are vegfr and mtor pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced rcc. treatment of advanced renal cell carcinoma.,

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - mycobacterium bovis (bacillus calmette and guerin (bcg) strain), quantity: 200000000 cfu - injection, powder for - excipient ingredients: citric acid monohydrate; ferric ammonium citrate; strong ammonia solution; purified water; asparagine; magnesium sulfate heptahydrate; zinc formate dihydrate; lactose monohydrate; dibasic potassium phosphate; glycerol - onco tice is used as a treatment of primary or recurrent carcinomain situ of the urinary bladder. onco tice is also used after transurethral resection for the prevention or recurrence of high grade and/or relapsing superficial papillary transitional cell carcinoma of the urinary bladder (viz papillary carcinoma stage ta or t1 - grades 1, 2, or 3) indications as at 3 october 2001: oncotice is used as a treatment ofthe urinary bladder. oncotice is also used after transurethral resection for the prevention of recurrence of high grade and/or relapsing superficial papillary transitional cell carinoma of the urinary bladder (viz papillary carcinoma stage ta (grade 2 or 3) or t1 (grade 1, 2, or 3). oncotice is only recommended for stage ta grade 1 tumours, when there is judged to be a high risk of tumour recurrence is considered likely. inidications as at 24 april 2002: oncotice is used as a treatment of primary of recurrent carcinoma in situ (cid) of the urinary bladder. oncotice is also used after transurethral resection for the prevention of recurrence of high grade and/or relapsing superficial papillary transitional cell carcinoma of the urinary bladder (viz papillary carcinoma stage ta (grade 2 or 3) or t1 (grade 1, 2, or 3). oncotice is only reccommended for stage ta grade 1 tumours, when there is judged to be a high risk of tumour recurrence.

Australia - English - Department of Health (Therapeutic Goods Administration)

jazz pharmaceuticals anz pty ltd - defibrotide, quantity: 200 mg - injection, concentrated - excipient ingredients: hydrochloric acid; sodium citrate dihydrate; sodium hydroxide; water for injections - defitelio is indicated for the treatment of severe hepatic veno-occlusive disease (vod) also known as sinusoidal obstruction syndrome (sos) in haematopoietic stem-cell transplantation (hsct) therapy.,it is indicated in adults and in adolescents, children and infants of 1 month of age and above.

United States - English - NLM (National Library of Medicine)

jazz pharmaceuticals, inc. - ziconotide acetate (unii: t2i226k69m) (ziconotide - unii:7i64c51o16) - ziconotide 25 ug in 1 ml - prialt (ziconotide) solution, intrathecal infusion is indicated for the management of severe chronic pain in adult patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. ziconotide was embryolethal in rats when given as a continuous intravenous infusion during the major period of organogenesis as evidenced by significant increases in post-implantation loss because of an absence or a reduced number of live fetuses. estimated exposure for embryolethality in the rat was approximately 700-fold above the expected exposure resulting from the maximum recommended human daily intrathecal dose of 0.8 mcg/hr (19.2 mcg/day). ziconotide was not teratogenic in female rats when given as a continuous intravenous infusion at doses up to 30 mg/kg/day or in female rabbits up to 5 mg/kg/day during the major period of organ development. estimated exposures in the female rat and rabbit were approxima

United States - English - NLM (National Library of Medicine)

allergan, inc. - linaclotide (unii: n0txr0xr5x) (linaclotide - unii:n0txr0xr5x) - linaclotide 145 ug - linzess is indicated for the treatment of: • irritable bowel syndrome with constipation (ibs-c) in adults • chronic idiopathic constipation (cic) in adults • functional constipation (fc) in pediatric patients 6 to 17 years of age linzess is contraindicated in: - patients less than 2 years of age due to the risk of serious dehydration [see warnings and precautions ( 5.1 ), use in specific populations ( 8.4 )] . - patients with known or suspected mechanical gastrointestinal obstruction.  risk summary linaclotide and its active metabolite are negligibly absorbed systemically following oral administration [see clinical pharmacology ( 12.3 )] , and maternal use is not expected to result in fetal exposure to the drug. the available data on linzess use in pregnant women are not sufficient to inform any drug-associated risk for major birth defects and miscarriage. in animal developmental studies, no effects on embryo-fetal development were observed with oral administration of linaclotide in rats and rabbits during o

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen healthcare ltd - linaclotide - oral capsule - 290microgram

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

vetafarm pty.ltd. - chlortetracycline hydrochloride - oral powder, pre-mix - chlortetracycline hydrochloride antibiotic active 100.0 mg/g - antibiotic & related - birds - ornamental | amazon parrot | caged bird | canary | cockatiel | cockatoo | conure | finch | lovebird | macaw | ornamental - antibiotic - anti-infective | abrasions | abscesses | airsacculitis | antiseptic | avian mycoplasmas | blackhead | body odours | bowed tendons | broad spectrum | burns | coccidiosis | coliform complex | conjunctivitis | cowpox | cracks | crusts | dandruff | dermatological disorders | dermatosis | dry skin | dysentery | eczema | endometritis | enteric diseases | enzootic pneumonia | feed efficiency | fungal infections | girth galls | infections | inflammed pads | itching | keratolytic | lacerations | mastitis | mycoplasmas | odours | open wounds | otitis | pruritis | queensland itch | respiratory disease | saddle rash | salmonellosis | scabs | scaly skin | sheath rot | skin irritations | sores | swine dysentery | teat cracking | teat infections | topical infections | udder sores | weight gain | wire cuts | wounds